These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10544592)

  • 1. [All use of new drugs should be registered. It's the only way to get early warning on unexpected adverse effects].
    Werkö L
    Lakartidningen; 1999 Oct; 96(40):4284-6. PubMed ID: 10544592
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sweden can contribute to safer drug assessment].
    Strandberg K
    Lakartidningen; 2006 Jun 8-13; 103(23):1853-5. PubMed ID: 16838598
    [No Abstract]   [Full Text] [Related]  

  • 3. [Classification and profile of adverse drug effects].
    Cordonnier M
    Bull Soc Belge Ophtalmol; 2007; (304):15-6. PubMed ID: 17718223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 5. [Reporting of incidents. Experiences with medical registration systems].
    Lipczak H; Schiøler T
    Ugeskr Laeger; 2001 Sep; 163(39):5350-5. PubMed ID: 11590948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-cultural miscommunication.
    Kang-Yum E
    Hastings Cent Rep; 1996; 26(3):46. PubMed ID: 8736674
    [No Abstract]   [Full Text] [Related]  

  • 9. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How to discover unexpected adverse effects? Heart valve lesions caused by appetite suppressants reported in the USA, but not in Europe].
    Rössner S
    Lakartidningen; 1999 Dec; 96(50):5654-5. PubMed ID: 10643234
    [No Abstract]   [Full Text] [Related]  

  • 12. New drugs: watch out for unexpected adverse effects.
    Prescrire Int; 2002 Oct; 11(61):150-1. PubMed ID: 12378747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 14. Global harmonization is not all that global: divergent approaches in drug safety.
    Castle GH; Kelly B
    Food Drug Law J; 2008; 63(3):601-22. PubMed ID: 19031662
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-marketing surveillance and adverse drug reactions.
    Shani S
    Isr Med Assoc J; 1999 Oct; 1(2):117-9. PubMed ID: 10731310
    [No Abstract]   [Full Text] [Related]  

  • 16. Diplopia and fluoroquinolones.
    Fraunfelder FW; Fraunfelder FT
    Ophthalmology; 2009 Sep; 116(9):1814-7. PubMed ID: 19643481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A decade of WHO Information Exchange System 'ALERT'.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1999 Aug; 18(3):117-9. PubMed ID: 10592833
    [No Abstract]   [Full Text] [Related]  

  • 18. Unlicensed to kill.
    Willis J
    Nurs Times; 2000 Apr 20-26; 96(16):29. PubMed ID: 11309936
    [No Abstract]   [Full Text] [Related]  

  • 19. The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study.
    Meijer WM; Cornel MC; Dolk H; de Walle HE; Armstrong NC; de Jong-van den Berg LT;
    Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):675-82. PubMed ID: 16761260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Increased significance of adverse effects of drugs--a threat to the industry].
    Werkö L
    Lakartidningen; 2004 Dec; 101(50):4134-6. PubMed ID: 15631270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.